pharma · Androgenetic Alopecia · Acute Myocardial Infarction
Dong Wang
Dong Wang is a pharma organization headquartered in CN. Primary therapeutic focus areas include Androgenetic Alopecia, Acute Myocardial Infarction, Type 2 Diabetes Mellitus, Postmenopausal Osteoporosis, Alzheimer's Disea
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 8
- Drugs
- 13
- Patents
- 0
DA-4001C
Phase 2 · small molecule · Androgenetic Alopecia
DA-4001C for Androgenetic Alopecia is a Phase 2 program (small_molecule) at Dong Wang with 1 ClinicalTrials.gov record(s).
Internal code DA4001_AGAP_POC
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Dong Wang
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Androgenetic Alopecia
- Status
- completed
- Trials
- 1